What is the patient acquisition cost for a pediatric clinic in India?

no published specialty benchmark exists; see CPQL benchmarks for national average methodology

Why pediatrics is a retention business first

Most healthcare specialties acquire a patient for a procedure or an episode of illness, and the acquisition cost is measured against that one event's value. Pediatrics doesn't work that way. A family that brings a newborn to a clinic returns on a schedule known years in advance — immunisation visits at fixed intervals through early childhood, then annual well-child checks through adolescence. No other specialty has a multi-year visit calendar built into standard care in the way pediatrics does. That changes what "acquisition cost" should be measured against: not the value of one visit, but the value of every visit across that calendar, assuming the clinic keeps the family.

What lifetime value looks like against a single acquisition cost

no published specialty benchmark exists; see CPQL benchmarks for national average methodology means there's no clean specialty-specific ratio to publish here. What can be said with confidence is directional: because the visit calendar is long and largely mandatory (immunisation schedules aren't optional in most families' minds), the lifetime value of a well-retained pediatric patient compounds well beyond what a single acquisition cost, however calculated, would suggest on its own. A clinic that acquires a family once and loses them after the first year has a very different economic outcome than one that retains them for a decade.

Recall systems matter more than ad spend

If pediatrics runs on a known visit calendar, the clinic's own recall system becomes the more important lever than acquisition spend. A clinic that reliably reminds families when the next immunisation or check-up is due retains more of its acquired patients than one that relies on families remembering by themselves. That means a chunk of what should be budgeted as "acquisition" economics is really a retention-system question — appointment reminders, recall calls, and a scheduling workflow that doesn't let a due visit slip. Spending more to acquire a new family while under-investing in recall for existing families is, in effect, paying twice for the same patient.

See CPQL benchmarks across specialties where ICG has agreed figures for comparison, and read the marketing cost page if the question is about total monthly spend rather than the acquisition-cost-versus-value calculation. More on pediatric-specific positioning is on the pediatrics industry page.

Frequently asked questions

Why doesn't ICG publish a pediatric CPQL number? No agreed figure exists across ICG's client base for this specialty — the sample either isn't large enough or the figures on file contradict each other, so ICG doesn't publish a number it can't stand behind.

Is a higher acquisition cost acceptable for a pediatric clinic than for other specialties? It can be, if retention across the visit calendar is strong, because the value being acquired isn't one visit — it's a multi-year relationship. The acquisition cost only looks high if it's measured against a single visit instead of the full calendar.

What matters more for a pediatric clinic's growth — new patient acquisition or retention? Both matter, but retention is the leverage point unique to pediatrics. A clinic can improve its economics substantially by fixing recall gaps even without spending more on new acquisition.

Does word-of-mouth reduce acquisition cost for pediatric clinics specifically? Referral tends to be strong in pediatrics because parents talk to other parents in the same life stage, which can lower blended acquisition cost over time relative to specialties with less natural referral overlap.

How does clinic location affect acquisition cost? A clinic in a dense residential area with many young families typically sees lower acquisition cost than one in a mixed-demographic area, simply because more of the immediate audience matches the target patient profile.

Written by Raman Soni. Reviewed by Abhash Kumar, Co-Founder, Strategy.

Detailed answers